StockData
Evommune, Inc. logo

Evommune, Inc. (EVMN) stock

EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$7.04−0.20 (-2.76%)

Close on Nov 20, 2026Market cap $255.50MP/E –Yield –

Evommune free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Evommune's free cash flow for the twelve months ending Sep 30, 2026 was -$91.00M. For fiscal 2025 it was -$76.68M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$76.68M–
FY2024Dec 31, 2024-$58.28M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$26.12M–
Q2 FY2026Jun 30, 2026-$20.50M–
Q1 FY2026Mar 31, 2026-$27.59M–
Q4 FY2025Dec 31, 2025-$16.80M–
Q3 FY2025Sep 30, 2025-$9.77M–
Q2 FY2025Jun 30, 2025-$26.21M–
Q1 FY2025Mar 31, 2025-$23.90M–
Q4 FY2024Dec 31, 2024-$18.51M–

More Evommune figures

See a number that looks wrong?